Procept secures FDA approval to study surgical robot in prostate cancer
Procept Biorobotics received FDA approval to start a pivotal trial of its robotic-assisted aquablation therapy in prostate cancer, aiming to compare it to radical prostatectomy. The trial targets men with localized prostate cancer likely to grow at a slow to moderate rate, potentially unlocking a $500 million market. Procept's therapy, already used for noncancerous prostate enlargement, seeks to personalize treatment by removing specific prostate areas while preserving erectile, ejaculatory, and continence functions. The trial will enroll up to 280 men, evaluating morbidity after six months and tracking patients for 10 years to assess treatment-related harm and oncologic events. The study aims to determine if aquablation can treat prostate cancer without the adverse effects of radical prostatectomy.
Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer
R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.
CVS Stock Gains From Its Birth Control Prescribing Service Launch
CVS Health introduced hormonal contraceptive prescribing service in Massachusetts, aiming to lower barriers for women needing birth control. This service addresses disparities in access, with nearly 400 CVS Pharmacy locations offering it.
SS Innovations expects FDA approval for surgical robot by the end of 2025
SS Innovations expects FDA approval for its Mantra surgical robot by end of 2025, following feedback from a pre-submission meeting. The company plans to submit for IDE in Q1 2025 to initiate clinical trials for various indications, leveraging ongoing clinical use in India and additional trials in the U.S.
The Role of Surgery in Lung Cancer Treatment
Non-small cell lung cancer (NSCLC) treatment has evolved with screening and systemic therapies, enabling earlier diagnosis and better management. Surgery remains key, adapting to cancer stages and patient needs, including palliative care. Innovations like minimally invasive surgery and enhanced recovery protocols improve outcomes and quality of life, reflecting NSCLC's chronic disease nature.
© Copyright 2025. All Rights Reserved by MedPath